Battelli, N.; Mocerino, C.; Montedoro, M.; Pistelli, M.; Portarena, I.; Rosanova, M.; Sidoni, T.; Vici, P.
New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III. Curr. Oncol. 2025, 32, 192.
https://doi.org/10.3390/curroncol32040192
AMA Style
Battelli N, Mocerino C, Montedoro M, Pistelli M, Portarena I, Rosanova M, Sidoni T, Vici P.
New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III. Current Oncology. 2025; 32(4):192.
https://doi.org/10.3390/curroncol32040192
Chicago/Turabian Style
Battelli, Nicola, Carmela Mocerino, Michele Montedoro, Mirco Pistelli, Ilaria Portarena, Mario Rosanova, Tina Sidoni, and Patrizia Vici.
2025. "New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III" Current Oncology 32, no. 4: 192.
https://doi.org/10.3390/curroncol32040192
APA Style
Battelli, N., Mocerino, C., Montedoro, M., Pistelli, M., Portarena, I., Rosanova, M., Sidoni, T., & Vici, P.
(2025). New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III. Current Oncology, 32(4), 192.
https://doi.org/10.3390/curroncol32040192
